VKTX — VIKING THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying VKTX?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their VKTX position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).
- +1 tracked investor added or increased positions last quarter (Ray Dalio)
- +4 tracked investors reported holding VKTX at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About VIKING THERAPEUTICS INC (VKTX)
VIKING THERAPEUTICS INC (VKTX) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $243M. Across recent filings, tracked investors recorded 4 new positions, 1 increased, 2 reduced, and 3 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in VKTX
How many top investors track VKTX
A small number of top investors own this.
VKTX Ownership Composition
How VIKING THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant97.7%
- Macro2.3%
Tracked investors currently reporting VKTX
4 tracked investors have since exited this position — listed separately below.
- Ken GriffinJun 30, 2026Citadel AdvisorsShares2.7MValue$104.4M% Portfolio0.01%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares514.9KValue$20.1M% Portfolio0.01%
- Steve CohenJun 30, 2026Point72 Asset ManagementShares508.6KValue$19.8M% Portfolio0.02%
- Ray DalioJun 30, 2026Bridgewater AssociatesShares87.9KValue$3.4M% Portfolio0.01%
Previously held VKTX
These investors reported VKTX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Andreas Halvorsen | Viking Global Investors | 721.9K | $45.7M | Sep 30, 2024 |
| Stanley Druckenmiller | Duquesne Family Office | 549.3K | $14.6M | Jun 30, 2025 |
| Paul Tudor Jones | Tudor Investment Corp | 97.2K | $2.6M | Sep 30, 2025 |
| George Soros | Soros Fund Management | 90K | $3.2M | Dec 31, 2025 |
Recent activity
- $0(-100.00%)Feb 14, 2025
- New$3.2MFeb 13, 2026
- Sold$0(-100.00%)May 15, 2026
- New$3.2MNov 13, 2025
- Reduced$3.6M(-16.06%)Feb 13, 2026
- Reduced$2.3M(-31.29%)May 15, 2026
- Increased$3.4M(23.35%)Aug 14, 2026
- $14.6MAug 15, 2025
- $0(-100.00%)Nov 14, 2025
- $45.7MNov 14, 2024
Frequently asked questions
- How many institutional investors hold VKTX?
- 4 tracked institutional investors disclosed a position in VKTX (VIKING THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of VKTX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in VKTX, valued at $243M.
- Did institutional ownership of VKTX increase or decrease?
- Across recent 13F filings, tracked investors recorded 4 new positions, 1 increased, 2 reduced, and 3 fully exited VKTX.
- Where does this VKTX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.